Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren

Published:2014-06-07 Issue:7 Volume:65 Page:582-589
ISSN:0017-8470
Container-title:Der Hautarzt
language:de
Short-container-title:Hautarzt

Author:

Gutzmer R.,Hassel J.C.,Kähler K.C.,Loquai C.,Mössner R.,Ugurel S.,Zimmer L.,der das ADO Für Komitee „Kutane Nebenwirkungen“

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s00105-013-2733-8.pdf

Reference45 articles.

1. Anforth R, Fernandez-Penas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14:e11–e18

2. Anforth RM, Blumetti TC, Kefford RF et al (2012) Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 167:1153–1160

3. Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283–e287

4. Ascierto PA, Schadendorf D, Berking C et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249–256

5. Balagula Y, Barth HK, Busam KJ et al (2011) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 29:1114–1121

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Oral Anti-Cancer Drugs and Medication Safety;Deutsches Ärzteblatt international;2019-11-15

2. A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia;Investigational New Drugs;2019-06-26

3. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors;European Journal of Dermatology;2019-01

4. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials;Oncotarget;2017-02-23

5. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis;Future Oncology;2015-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3